【AI详解】Addressing the Cold Reality of mRNA Vaccine Stability.

文献信息

一句话小结

本文回顾了mRNA疫苗在COVID-19疫情中的应用，指出其在储存稳定性方面面临挑战，并强调目前缺乏系统识别mRNA疫苗降解机制的方法。研究呼吁在药物开发中优先设计可在冷藏或常温下有效存储的mRNA疫苗配方，以应对未来疫情的需求。

在麦伴科研 (maltsci.com) 搜索更多文献

COVID-19 · 冷链 · 配方 · 脂质纳米颗粒 · 保质期

摘要

随着mRNA疫苗在应对COVID-19疫情的晚期临床试验中成为领先者，其配方和稳定性方面的挑战也显而易见。在本评论中，我们首先基于可获得的公开信息描述了各公司关于mRNA疫苗药品在疫苗供应链中（冷冻）储存的提案。接着，我们回顾了关于mRNA疫苗候选药物药物稳定性的文献，包括改善其稳定性的尝试、监测其稳定性的分析技术以及涵盖产品特性和储存稳定性的监管指南。我们得出结论，目前缺乏系统的方法来识别制备的mRNA疫苗候选药物的关键物理化学降解机制。因此，在药物开发领域，合理设计在冷藏或常温下储存、运输和施用的最佳稳定化mRNA疫苗配方应当成为首要任务。除了对多种病毒病原体的人类免疫原性证据，包括针对COVID-19的有力疗效结果之外，mRNA疫苗方法的另一个关键优势在于其可以迅速调整以应对新兴传染病的未来疫情。因此，我们不应等待下一个大流行来解决与制备的mRNA疫苗稳定性和储存相关的挑战。

英文摘要

As mRNA vaccines became the frontrunners in late-stage clinical trials to fight the COVID-19 pandemic, challenges surrounding their formulation and stability became readily apparent. In this commentary, we first describe company proposals, based on available public information, for the (frozen) storage of mRNA vaccine drug products across the vaccine supply chain. We then review the literature on the pharmaceutical stability of mRNA vaccine candidates, including attempts to improve their stability, analytical techniques to monitor their stability, and regulatory guidelines covering product characterization and storage stability. We conclude that systematic approaches to identify the key physicochemical degradation mechanism(s) of formulated mRNA vaccine candidates are currently lacking. Rational design of optimally stabilized mRNA vaccine formulations during storage, transport, and administration at refrigerated or ambient temperatures should thus have top priority in the pharmaceutical development community. In addition to evidence of human immunogenicity against multiple viral pathogens, including compelling efficacy results against COVID-19, another key strength of the mRNA vaccine approach is that it is readily adaptable to rapidly address future outbreaks of new emerging infectious diseases. Consequently, we should not wait for the next pandemic to address and solve the challenges associated with the stability and storage of formulated mRNA vaccines.

麦伴智能科研服务

主要研究问题

1. mRNA疫苗的稳定性如何影响其在不同温度下的运输和存储？
2. 有哪些新兴技术可以提高mRNA疫苗的稳定性和有效性？
3. 在mRNA疫苗的药物开发过程中，如何评估其物理化学降解机制？
4. 目前有哪些法规指导mRNA疫苗的产品特性和存储稳定性？
5. 如何通过合理设计来优化mRNA疫苗的配方，以应对未来疫情的挑战？

核心洞察

研究背景和目的

随着mRNA疫苗在COVID-19疫情中的迅速发展，其稳定性和储存条件成为关键问题。本文旨在探讨mRNA疫苗的稳定性，分析当前储存方案，评估其在疫苗供应链中的影响，并提出未来研究方向。

主要方法/材料/实验设计

研究采用文献综述的方式，分析了mRNA疫苗的储存条件、稳定性以及相关的分析技术。重点包括：

• 疫苗设计与储存方案：总结了Moderna、Pfizer-BioNTech和CureVac等公司的储存建议。
• 稳定性研究：回顾了文献中关于mRNA疫苗候选药物的稳定性研究，包括改善稳定性的方法和监测技术。
• 监管指导：分析了FDA和EMA关于mRNA疫苗的监管框架及其稳定性测试的要求。

关键结果和发现

1. 储存条件：mRNA疫苗通常需要在-80°C至-60°C的条件下储存。不同厂商提供的储存方案在时间和温度上存在差异。
2. 稳定性研究缺乏：目前针对mRNA疫苗最终产品的稳定性研究相对稀缺，主要集中在mRNA本身的稳定性上。
3. 改善措施：使用冻干技术和保护剂（如糖类）可提高mRNA疫苗的稳定性，然而缺乏系统性的机制研究。

主要结论/意义/创新性

mRNA疫苗在COVID-19防控中展现出良好的免疫原性和有效性，但其储存和稳定性问题亟待解决。为了确保疫苗能够在全球范围内有效分发，开发能够在更高温度下稳定储存的第二代mRNA疫苗应成为研发的重点。作者强调不应等到下一个疫情爆发才解决这些问题，而应立即采取措施。

研究局限性和未来方向

• 局限性：目前关于mRNA疫苗稳定性的研究仍处于初级阶段，缺乏全面的机制性分析。
• 未来方向：未来的研究应集中在：
  • 系统性分析mRNA的化学和物理降解路径。
  • 开发能够在常温或冷藏条件下储存的疫苗。
  • 提高疫苗在运输和使用过程中的稳定性。

通过上述措施，可以为未来mRNA疫苗的广泛应用奠定基础，确保其在应对全球公共卫生危机中的有效性。

参考文献

1. Challenges and advances towards the rational design of mRNA vaccines. - Charlotte Pollard;Stefaan De Koker;Xavier Saelens;Guido Vanham;Johan Grooten - Trends in molecular medicine (2013)
2. Optimization of Lipid Nanoparticles for Intramuscular Administration of mRNA Vaccines. - Kimberly J Hassett;Kerry E Benenato;Eric Jacquinet;Aisha Lee;Angela Woods;Olga Yuzhakov;Sunny Himansu;Jessica Deterling;Benjamin M Geilich;Tatiana Ketova;Cosmin Mihai;Andy Lynn;Iain McFadyen;Melissa J Moore;Joseph J Senn;Matthew G Stanton;Örn Almarsson;Giuseppe Ciaramella;Luis A Brito - Molecular therapy. Nucleic acids (2019)
3. Long-term storage of DNA-free RNA for use in vaccine studies. - Kathryn L Jones;Debbie Drane;Eric J Gowans - BioTechniques (2007)
4. A thermostable messenger RNA based vaccine against rabies. - Lothar Stitz;Annette Vogel;Margit Schnee;Daniel Voss;Susanne Rauch;Thorsten Mutzke;Thomas Ketterer;Thomas Kramps;Benjamin Petsch - PLoS neglected tropical diseases (2017)
5. mRNA vaccines - a new era in vaccinology. - Norbert Pardi;Michael J Hogan;Frederick W Porter;Drew Weissman - Nature reviews. Drug discovery (2018)
6. Chemical stability of nucleic acid-derived drugs. - D Pogocki;C Schöneich - Journal of pharmaceutical sciences (2000)
7. The effect of secondary structure on cleavage of the phosphodiester bonds of RNA. - S Mikkola;U Kaukinen;H Lönnberg - Cell biochemistry and biophysics (2001)
8. Delivering the Messenger: Advances in Technologies for Therapeutic mRNA Delivery. - Piotr S Kowalski;Arnab Rudra;Lei Miao;Daniel G Anderson - Molecular therapy : the journal of the American Society of Gene Therapy (2019)
9. Considerations for Producing mRNA Vaccines for Clinical Trials. - Andreas Schmid - Methods in molecular biology (Clifton, N.J.) (2017)
10. The European Regulatory Environment of RNA-Based Vaccines. - Thomas Hinz;Kajo Kallen;Cedrik M Britten;Bruno Flamion;Ulrich Granzer;Axel Hoos;Christoph Huber;Samir Khleif;Sebastian Kreiter;Hans-Georg Rammensee;Ugur Sahin;Harpreet Singh-Jasuja;Özlem Türeci;Ulrich Kalinke - Methods in molecular biology (Clifton, N.J.) (2017)

引用本文的文献

1. Sterilizing Immunity against SARS-CoV-2 Infection in Mice by a Single-Shot and Lipid Amphiphile Imidazoquinoline TLR7/8 Agonist-Adjuvanted Recombinant Spike Protein Vaccine*. - Sonia Jangra;Jana De Vrieze;Angela Choi;Raveen Rathnasinghe;Gabriel Laghlali;Annemiek Uvyn;Simon Van Herck;Lutz Nuhn;Kim Deswarte;Zifu Zhong;Niek N Sanders;Stefan Lienenklaus;Sunil A David;Shirin Strohmeier;Fatima Amanat;Florian Krammer;Hamida Hammad;Bart N Lambrecht;Lynda Coughlan;Adolfo García-Sastre;Bruno G De Geest;Michael Schotsaert - Angewandte Chemie (International ed. in English) (2021)
2. Response to: Regarding the Article: Coronavirus Disease (COVID-19): Current Status and Prospects for Drug and Vaccine Development. - Kevin Ita - Archives of medical research (2021)
3. mRNA vaccine for cancer immunotherapy. - Lei Miao;Yu Zhang;Leaf Huang - Molecular cancer (2021)
4. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility. - Mark Eccleston-Turner;Harry Upton - The Milbank quarterly (2021)
5. Development of thermostable vaccine adjuvants. - Yizhi Qi;Christopher B Fox - Expert review of vaccines (2021)
6. Tamper-Proof Time-Temperature Indicator for Inspecting Ultracold Supply Chain. - Lam Tan Hao;Minkyung Lee;Hyeonyeol Jeon;Jun Mo Koo;Sung Yeon Hwang;Dongyeop X Oh;Jeyoung Park - ACS omega (2021)
7. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. - Kathrin Leppek;Gun Woo Byeon;Wipapat Kladwang;Hannah K Wayment-Steele;Craig H Kerr;Adele F Xu;Do Soon Kim;Ved V Topkar;Christian Choe;Daphna Rothschild;Gerald C Tiu;Roger Wellington-Oguri;Kotaro Fujii;Eesha Sharma;Andrew M Watkins;John J Nicol;Jonathan Romano;Bojan Tunguz;Eterna Participants;Maria Barna;Rhiju Das - bioRxiv : the preprint server for biology (2021)
8. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability. - Linde Schoenmaker;Dominik Witzigmann;Jayesh A Kulkarni;Rein Verbeke;Gideon Kersten;Wim Jiskoot;Daan J A Crommelin - International journal of pharmaceutics (2021)
9. Perspectives on RNA Vaccine Candidates for COVID-19. - Pobitra Borah;Pran Kishore Deb;Nizar A Al-Shar’i;Lina A Dahabiyeh;Katharigatta N Venugopala;Vinayak Singh;Pottathil Shinu;Snawar Hussain;Satyendra Deka;Balakumar Chandrasekaran;Da’san M M Jaradat - Frontiers in molecular biosciences (2021)
10. mRNA vaccines for COVID-19: what, why and how. - Jung Woo Park;Philip N P Lagniton;Yu Liu;Ren-He Xu - International journal of biological sciences (2021)

… (220 更多 篇文献)

© 2025 MaltSci 麦伴科研 - 我们用人工智能技术重塑科研